GlassScriptPhysician profile
Lisa Marquez
NPI 1790068435
$2,876.50
in general payments reported to CMS, 2019-2025
21 companies · $613 in 2025
The $613 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $633 · 2022: $657 · 2023: $400 · 2024: $574 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.23 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $694.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $401.75 | 2021-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $401.41 | 2022-2023 | |
| Lilly USA, LLC | $372.07 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $140.00 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $133.09 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $128.07 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $117.34 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.80 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.74 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $51.08 | 2024-2025 | Rexulti |
| Abbott Laboratories | $43.58 | 2024-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $37.22 | 2023 | Opticross 35, Imager II |
| Exact Sciences Corporation | $32.30 | 2024 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $27.71 | 2024 | Immunocap |
| Dexcom, INC. | $24.43 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $20.18 | 2024 | Capvaxive |
| Glaxosmithkline, LLC. | $16.90 | 2022 | |
| Medtronic, INC. | $13.04 | 2022 | |
| Astellas Pharma US INC | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.